Company intelligence / Profile preview

Pell Bio-Med Technology Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Pell Bio-Med Technology is developing advanced cell therapies for oncology and regenerative medicine. Its lead program is a CD19-targeting CAR-T therapy in Phase 2 clinical trials for follicular lymphoma. Other pipeline assets include preclinical programs targeting rheumatoid arthritis, thyroid cancer, and other cancers using various cell-based modalities such as gene-modified ADSCs and anti-mesothelin CAR-T cells. The company also offers commercial products related to tissue practice laboratory infrastructure and stem cell applications.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapy (including autologous T cell therapy, CAR-T, CAR-NK, CAR-γδT)Adipose-derived stem cells (ADSC)Synthetic peptide
Industry: Biotech

Drug pipeline

3 assets

PL001

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Pell Bio-Med Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pell Bio-Med Technology Co., Ltd..